Confronto
Mazdutide vs. Semaglutid
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Metabolico
Metabolico
N. CAS
2259884-03-0
910463-68-2
Peso molecolare
4790 g/mol
4113.6 g/mol
Emivita
132 h
165 h
Sequenza
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit Fettsäureseitenkettemodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMeccanismo d'azione
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
4
3
Effetti registrati
4
3
Contraddizioni aperte
0
1
Eventi avversi documentati
0
5
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Mazdutide and Semaglutid?
- Mazdutide is classified as "Metabolico", while Semaglutid is classified as "Metabolico". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Mazdutide or Semaglutid?
- The highest available evidence level is "RCT sull'uomo" for Mazdutide and "RCT sull'uomo" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Mazdutide and Semaglutid in Germany and the United States?
- Germania: Mazdutide — Solo ricerca, Semaglutid — Su prescrizione. Stati Uniti: Mazdutide — Solo ricerca, Semaglutid — Su prescrizione. These are factual summaries with source and review date on the individual pages.